Literature DB >> 10597871

Assessing the cardiac safety of ebastine. Epilogue.

D J Roberts1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10597871     DOI: 10.2165/00002018-199921001-00011

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


× No keyword cloud information.
  19 in total

1.  Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia.

Authors:  J Morganroth; F V Brozovich; J T McDonald; R A Jacobs
Journal:  Am J Cardiol       Date:  1991-04-01       Impact factor: 2.778

Review 2.  Blockade of cardiac potassium and other channels by antihistamines.

Authors:  E Delpón; C Valenzuela; J Tamargo
Journal:  Drug Saf       Date:  1999       Impact factor: 5.606

Review 3.  Cardiac effects of ebastine and other antihistamines in humans.

Authors:  A J Moss; J Morganroth
Journal:  Drug Saf       Date:  1999       Impact factor: 5.606

4.  Some observations on the cardiotoxic and drug interaction profiles of second generation antihistamines as measured in the guinea pig.

Authors:  D J Roberts; J Llenas
Journal:  Arzneimittelforschung       Date:  1996-08

5.  Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental animal model of torsade de pointes.

Authors:  J A Hey; M del Prado; W Kreutner; R W Egan
Journal:  Arzneimittelforschung       Date:  1996-02

6.  Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects.

Authors:  J A Hey; M del Prado; J Sherwood; W Kreutner; R W Egan
Journal:  Arzneimittelforschung       Date:  1996-02

7.  Suppression of mammalian K+ channel family by ebastine.

Authors:  C M Ko; I Ducic; J Fan; Y M Shuba; M Morad
Journal:  J Pharmacol Exp Ther       Date:  1997-04       Impact factor: 4.030

Review 8.  Rate-corrected QT interval: techniques and limitations.

Authors:  C Funck-Brentano; P Jaillon
Journal:  Am J Cardiol       Date:  1993-08-26       Impact factor: 2.778

Review 9.  Variations among non-sedating antihistamines: are there real differences?

Authors:  M J Mattila; I Paakkari
Journal:  Eur J Clin Pharmacol       Date:  1999-04       Impact factor: 2.953

10.  Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines.

Authors:  M Taglialatela; A Pannaccione; P Castaldo; G Giorgio; Z Zhou; C T January; A Genovese; G Marone; L Annunziato
Journal:  Mol Pharmacol       Date:  1998-07       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.